The FDA’s Next Steps on CBD—Q1 and Q2 2021 Will Be Critical

To be blunt, the FDA does NOT have a negative overall position on CBD. While the FDA has hit certain companies for violating laws that prohibit unproven medical claims, they are doing their due diligence on violators. Read on as GVB details the FDA and their positive perspective toward CBD, but is hampered by existing pharmaceutical law.

https://www.gvbbiopharma.com/the-fdas-next-steps-on-cbd-q1-and-q2-2021-will-be-critical/?fbclid=IwAR3qinffMx5qLDFdWJWJSVsV4qYe95SR3PsOoSl61iSGF1GME0yz5mtLCcg